A randomised, double-blind, placebo-controlled phase 3 study investigating the efficacy of nicotine substitution (NS) on nicotine withdrawal symptoms (NWS) in hospitalised smokers (HS)
K. Nackaerts, B. Salhi, A. Devolder, M. Meysman, H. Boudrez, L. Van Dyck, L. Demoulin, H. Vanderschelde, G. Van Maele, J. Van Meerbeeck (Leuven, Ghent, Edegem, Brussels, Belgium)
Source: Annual Congress 2009 - Smoking cessation
Session: Smoking cessation
Session type: Oral Presentation
Number: 4632
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Nackaerts, B. Salhi, A. Devolder, M. Meysman, H. Boudrez, L. Van Dyck, L. Demoulin, H. Vanderschelde, G. Van Maele, J. Van Meerbeeck (Leuven, Ghent, Edegem, Brussels, Belgium). A randomised, double-blind, placebo-controlled phase 3 study investigating the efficacy of nicotine substitution (NS) on nicotine withdrawal symptoms (NWS) in hospitalised smokers (HS). Eur Respir J 2009; 34: Suppl. 53, 4632
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
A multicenter, randomised, double-blind, placebo-controlled 6 month trial to evaluate efficacy and tolerability of bupropion hydrochloride sustained release (SR) tablets as treatment for nicotine dependency in healthcare workers and as an aid to smoking Source: Eur Respir J 2002; 20: Suppl. 38, 611s Year: 2002
Efficacy and safety of revefenacin (REV), a long-acting muscarinic antagonist for nebulization: results of replicate randomized, double-blind, placebo-controlled, parallel-group phase 3 trials in participants with moderate to very severe COPD Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017
The use of modafinil in patients with obstructive apnoea-hyponoea syndrome (OAHS). A randomized, placebo-controlled, double-blind study Source: Eur Respir J 2001; 18: Suppl. 33, 419s Year: 2001
Effects of a concomitant therapy with Cineole (Eucalyptole) on exacerbation rate in COPD: A placebo-controlled double-blind trial Source: Annual Congress 2010 - COPD exacerbation Year: 2010
PULSAR: A phase 2, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of sotatercept (ACE-011) when added to standard of care (SOC) for treatment of pulmonary arterial hypertension (PAH) Source: International Congress 2019 – Pulmonary hypertension: clinical Year: 2019
A multicenter, randomized, double-blind, double-dummy, 2-way crossover, single dose study, comparing the efficacy and safety of the fluticasone/salmeterol (500/50 μg) combination administered with the new Elpenhaler inhalation device versus the innovative one in patients with asthma Source: Annual Congress 2009 - Quality of treatment in primary respiratory care Year: 2009
Efficacy of a nicotine mouth spray in smoking cessation: a randomised, double-blind trial}, Source: Eur Respir J 2012; 40: 548-554 Year: 2012
Fixed combination of glycopyrrolate and formoterol MDI (GFF-MDI) demonstrates superior inspiratory capacity (IC) compared to tiotropium DPI (Tio) following 7 days dosing, in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011
PRAISE, a randomized, placebo-controlled, double-blind Phase 2 clinical trial of pamrevlumab (FG-3019) in IPF patients Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017
Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial Source: Eur Respir J, 54 (4) 1901030; 10.1183/13993003.01030-2019 Year: 2019
Omalizumab efficacy following cat allergen exposure: Results from a randomized, double-blind, placebo-controlled, parallel-group study in patients with moderate asthma Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010
Glycopyrrolate MDI demonstrates comparable efficacy and safety to tiotropium DPI in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011
Effect of pre-treatment with the nicotine patch on withdrawal symptoms in smokers subsequently quitting with the nicotine patch: a double-blind randomised controlled trial Source: Eur Respir J 2002; 20: Suppl. 38, 612s Year: 2002
Azithromycin for treatment of hospitalised COVID-19 patients: a randomised, multicentre, open-label clinical trial (DAWn-AZITHRO) Source: ERJ Open Res, 8 (1) 00610-2021; 10.1183/23120541.00610-2021 Year: 2022
“Stepping down” in mild-to-moderate asthmatic children being well controlled while receiving low doses of inhaled corticosteroids (ICS): Daily vs. cyclical ICS administration (prospective, randomized, multicentre, open-label trial) Source: Annual Congress 2013 –Asthma treatment and management in children Year: 2013
Efficacy and safety of a novel nicotine mouth spray in smoking cessation: A randomized, placebo-controlled, double blind, multicenter study with 52-week follow up Source: Annual Congress 2011 - Smoking cessation science Year: 2011
Detrimental effects of β-blockers in COPD: a concern for nonselective β-blockers: a randomised, placebo controlled, cross-over study Source: Eur Respir J 2003; 22: Suppl. 45, 49s Year: 2003
Randomized, double blind, double dummy, placebo-controlled trial designed for comparing the effectiveness of formoterol (Foradil®) Aerolizer® and ipatropium bromide plus nebulized fenoterol (Berodual®) in asthma patients with ages ranging between 5 and 12 years who suffer acute asthma Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010